Literature DB >> 1288272

How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach.

E J Feuer1, L M Wun.   

Abstract

Largely unexplained increases in breast cancer incidence of about 1% per year have been documented back to the 1940s. Since 1982, breast cancer incidence in women aged 40 years and above has been increasing at a faster rate than this long-term secular trend, especially in women aged 60 years and above. Increases in the use of mammography since 1982 (which have been documented in population surveys of women) provide the most plausible explanation for the incidence increase over the long-term secular trend. A study by White et al. (J Natl Cancer Inst 1990;82:1546-52) found that, for women aged 45-64 years, the increase in mammography utilization could explain the incidence increase, while for women aged 65-74 years, it could account for only half the increase. The authors have developed an alternative model to that of White et al. that incorporates estimates of differential lead time (time from screen detection to clinical detection in the absence of screening) by age group. Using this model, the authors show that if older women have longer lead times, than similar increases in mammography utilization across age groups will lead to a larger incidence increase in older women. Thus, the observed increases in mammography utilization are generally concordant with increases in incidence, even in the older age groups.

Entities:  

Mesh:

Year:  1992        PMID: 1288272     DOI: 10.1093/oxfordjournals.aje.a116463

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  33 in total

1.  Age at diagnosis and multiple primary cancers of the breast and ovary.

Authors:  P J Suris-Swartz; J M Schildkraut; M F Vine; I Hertz-Picciotto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 2.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.

Authors:  Ruth Etzioni; Roman Gulati; Leslie Mallinger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

3.  Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.

Authors:  Roman Gulati; Eric J Feuer; Ruth Etzioni
Journal:  Am J Epidemiol       Date:  2016-06-29       Impact factor: 4.897

4.  What is the sensitivity of mammography and dynamic MR imaging for DCIS if the whole-breast histopathology is used as a reference standard?

Authors:  F Sardanelli; L Bacigalupo; L Carbonaro; A Esseridou; G M Giuseppetti; P Panizza; V Lattanzio; A Del Maschio
Journal:  Radiol Med       Date:  2008-07-09       Impact factor: 3.469

Review 5.  Putting the risk of breast cancer in perspective.

Authors:  J P Bunker; J Houghton; M Baum
Journal:  BMJ       Date:  1998-11-07

6.  Incidence trends of female breast cancer in Saskatchewan, 1932-1990.

Authors:  P P Wang; Y Cao
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Occupational risk factors for female breast cancer: a review.

Authors:  M S Goldberg; F Labrèche
Journal:  Occup Environ Med       Date:  1996-03       Impact factor: 4.402

8.  Recent trends in breast cancer mortality among white and black US women.

Authors:  F Chevarley; E White
Journal:  Am J Public Health       Date:  1997-05       Impact factor: 9.308

9.  Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.

Authors:  Clyde B Schechter; Aimee M Near; Jinani Jayasekera; Young Chandler; Jeanne S Mandelblatt
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

Review 10.  Studying environmental influences and breast cancer risk: suggestions for an integrated population-based approach.

Authors:  R Millikan; E DeVoto; B Newman; D Savitz
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.